Form 8-K - Current report:
SEC Accession No. 0001213900-24-105644
Filing Date
2024-12-04
Accepted
2024-12-04 16:30:57
Documents
14
Period of Report
2024-12-02
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0223687-8k_nkgen.htm   iXBRL 8-K 28049
  Complete submission text file 0001213900-24-105644.txt   247664

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nkgn-20241202.xsd EX-101.SCH 3882
3 XBRL DEFINITION FILE nkgn-20241202_def.xml EX-101.DEF 26779
4 XBRL LABEL FILE nkgn-20241202_lab.xml EX-101.LAB 37008
5 XBRL PRESENTATION FILE nkgn-20241202_pre.xml EX-101.PRE 25403
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0223687-8k_nkgen_htm.xml XML 6001
Mailing Address 3001 DAIMLER ST, SANTA ANA CA 92705
Business Address 3001 DAIMLER ST, SANTA ANA CA 92705 (949) 396-6830
NKGen Biotech, Inc. (Filer) CIK: 0001845459 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40427 | Film No.: 241526598
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)